Servier Acquires Promising Fragile X Syndrome Treatment, Key Genetic Cause of Autism
Servier, an international pharmaceutical group, has announced the acquisition of KER-0193, a promising potential treatment for Fragile X syndrome (FXS) from UK-based biotech Kaerus…
Read More...
Read More...
